Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Morning Markets March E-Mini S&P 500 futures (ESH24 ) are down -0.03%, and March Nasdaq 100 E-Mini futures (NQH24 ) are up +0.07%. Stock index futures this morning are little changed after mixed corporate...
Executive changes and a bullish analyst take combined to boost sentiment on the company.
Is the stock's risk worth the potential reward?
The stock bounced back Tuesday from a three-month low it hit on Monday.
The company announced early phase 2 trials information regarding its lead therapy.
These stocks climbed 74% and 78% over the past month and there could be more gains ahead.
The company, which specializes in autoimmune disorders affecting the kidney, benefited from a renewed interest in kidney therapies.
Vera Therapeutics (VERA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. ("Vera" or the "Company") (NASDAQ: VERA). Such...